Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states

E N Sarno, G E Grau, L M Vieira, J A Nery, E N Sarno, G E Grau, L M Vieira, J A Nery

Abstract

The possible role of cytokines in leprosy reactions was investigated by analysing the levels of tumour necrosis factor (TNF) and interleukin-1 (IL-1) in serum samples from 39 leprosy patients, 22 of them presenting either type I (upgrading) or type II (ENL) reactions. Fifty per cent of the patients showed elevated concentrations of TNF and IL-1 in at least one of the serum samples tested. This included all four patients undergoing type I reversal reaction and nine (50%) of the ENL patients studied. Concentrations of TNF above 1000 pg/ml were found in four patients with ENL. Development of erythema multiforme in these ENL patients represented an aggravating factor and all four patients suffering from this type of lesion demonstrated increased serum TNF levels. All BT patients tested presented elevated IL-1 levels, while only half of them presented elevated levels of TNF. No correlation was found between any particular systemic symptoms and the levels of TNF and IL-1. These results suggest that TNF and IL-1 may be implicated in leprosy reactions, either acting directly or in synergism with other cytokines.

References

    1. Br Med Bull. 1987 Apr;43(2):350-70
    1. Int J Lepr Other Mycobact Dis. 1987 Mar;55(1):36-41
    1. J Leukoc Biol. 1988 May;43(5):429-35
    1. Cell. 1988 Jul 15;54(2):141-2
    1. Int J Dermatol. 1987 Jun;26(5):278-85
    1. Science. 1987 Sep 4;237(4819):1210-2
    1. Int J Dermatol. 1987 Sep;26(7):436-7
    1. Int J Lepr Other Mycobact Dis. 1987 Sep;55(3):481-93
    1. J Exp Med. 1987 Nov 1;166(5):1280-9
    1. N Engl J Med. 1988 Aug 18;319(7):397-400
    1. J Exp Med. 1989 Jan 1;169(1):333-8
    1. Ann N Y Acad Sci. 1988;540:568-70
    1. J Invest Dermatol. 1989 Mar;92(3):348-54
    1. J Infect Dis. 1989 Apr;159(4):787-90
    1. Int Arch Allergy Appl Immunol. 1989;88(1-2):34-9
    1. Clin Immunol Immunopathol. 1989 Jun;51(3):419-25
    1. N Engl J Med. 1989 Jun 15;320(24):1586-91
    1. Immunol Today. 1989 Feb;10(2):61-6
    1. Immunology. 1989 Oct;68(2):196-8
    1. J Biol Chem. 1990 Jan 25;265(3):1531-6
    1. J Clin Invest. 1990 May;85(5):1694-7
    1. Proc Natl Acad Sci U S A. 1990 Jul;87(13):5188-92
    1. Clin Exp Immunol. 1989 Nov;78(2):224-9
    1. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255-73
    1. Prog Allergy. 1978;25:211-42
    1. Infect Immun. 1984 Sep;45(3):787-9
    1. Lepr Rev. 1985 Mar;56(1):35-9
    1. J Exp Med. 1986 Mar 1;163(3):740-5
    1. J Exp Med. 1986 Jun 1;163(6):1363-75
    1. Am J Pathol. 1986 Aug;124(2):179-85
    1. Lancet. 1986 Dec 13;2(8520):1364-5
    1. Lancet. 1987 Feb 14;1(8529):355-7
    1. N Engl J Med. 1987 Feb 12;316(7):379-85
    1. J Clin Invest. 1988 May;81(5):1506-10

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe